Since 2013, clinical practice guidelines recommend EGFR mutation testing of non-squamous NSCLC to select advanced-stage patients for first-line treatment using EGFR-TKIs.We aimed to determine population-based trends in the real-world uptake and impact in routine practice of these recently updated ...
参考文献: [1]Subramanian J, Leighl NB, Choi YL, et al. Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study[J]. Lung Cancer. 2022 Nov ...
5. Keedy VL, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 2011:29;2121-27. 6....
2023年12月,基于FLAURA2研究,奥希替尼联合化疗作为1类推荐中"其他推荐方案",被纳入《NCCN临床实践指南》(NCCN Guidelines®),用于治疗伴有EGFR Exon 19 Del/Exon 21 L858R突变的非小细胞肺癌患者[6]。 美国注册申请文件正处于Orbis项目的审查中,该项目旨在为监管机构提供一个针对肿瘤药物的共同提交和审批的协作框架。
American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 2011:29;2121-27. 6. NCCN, National ...
[9] Sholl LM, Aisner DL, Varella-Garcia M, et al. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol 2015;10:768-777. [10] Yu PP, Vose JM, Hayes DF. Genetic Cancer Susceptibility Testing: Increased ...
(copies/20 μL) based on the Poisson distribution35. The details of the specific mutations detected by the assay are provided in Table1and Supplementary TableS1. The non-clinical performance studies followed the guidelines approved by the Clinical and Laboratory Standards Institute (CLSI) and ...
1 For 2L treatment in mNSCLC with activating EGFR mutations, ESMO guidelines recommend T790M mutation testing using initial liquid biopsy in case of EGFR-TKI resistance in those patients not previously treated with osimertinib.1 Osimertinib is recommended for patients with a T790M+ mutation. In those...
15. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-Small Cell Lung Cancer. Version 3.2023, April 13, 2023 16. Passaro, A, Leighl N, Blackhall F, et al. ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer. Ann Oncol. 2022 ...
Overall, the results of the EQA suggest that there is more work to be done if laboratories are to ensure that the quality of their EGFR mutation testing meets an acceptable standard, as only 72 out of 91 (72%) of the laboratories passed the EQA and is in line with the findings of oth...